Cingulate
A biopharmaceutical company focused on the development of new product candidates for the treatment of central nervous system and neurobiological disorders.
Cingulate currently has two product candidates for the treatment of attention deficit hyperactivity disorder (ADHD).
Its lead product candidate, CTx-1301, utilizes the company’s proprietary PTR drug delivery platform to create a breakthrough, multi-core formulation of the active pharmaceutical ingredient dexmethylphenidate, a compound approved in the USA for the treatment of ADHD.
The company is headquartered in Kansas City, USA.
Latest Cingulate News & Features
18 January 2024
4 December 2023
13 March 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze